Paul Urick - Diplomat Pharmacy President
President
Mr. Paul Urick is President of the Company, since November 1, 2016. Mr. Urick works closely with Diplomats operations, clinical services, and sales teams, as well as industry partners. He has spent more than two decades building indepth knowledge and key relationships in specialty pharmacy, managed markets, and integrated health systems. Mr. Urick served as vice president of Industry Relations, Pharmaceutical Account Management, and Payor Strategies upon our acquisition of Burmans in June 2015. He was promoted to senior vice president in February 2016. In that role, he provided overall strategy and execution for all pharmaceutical and payor partners. Mr. Urick was president of managed markets and industry relations for Burmans from September 2014 until its acquisition by us. Before that role, beginning May 2011, he served as senior vice president of pharmacy operations for Cigna Corporationrationration, a healthcare company serving more than 15 million customers. He led Cignas internal PBM and home delivery operations. From 2004 to 2011, Mr. Urick was senior vice president of pharmacy services at Independence Blue Cross. During his tenure, he served as president for FutureScripts and FutureScripts Secure, two PBM companies he incorporated. In addition, Mr. Urick spent 10 years at Geisinger Health System, a leading integrated health services organization. There, he transformed and insourced PBM operations for Geisinger Health Plan. Mr. Urick is a member of the Academy of Managed Care Pharmacy, the National Association of Specialty Pharmacy, and other national associations. since 2016.
| Age | 44 |
| Tenure | 8 years |
| Phone | 888 720-4450 |
| Web | www.diplomat.is |
Diplomat Pharmacy Management Efficiency
The company has return on total asset (ROA) of (0.2088) % which means that it has lost $0.2088 on every $100 spent on assets. This is way below average. Diplomat Pharmacy's management efficiency ratios could be used to measure how well Diplomat Pharmacy manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 586.51 M in liabilities with Debt to Equity (D/E) ratio of 447.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Diplomat Pharmacy has a current ratio of 0.54, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Diplomat Pharmacy until it has trouble settling it off, either with new capital or with free cash flow. So, Diplomat Pharmacy's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Diplomat Pharmacy sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Diplomat to invest in growth at high rates of return. When we think about Diplomat Pharmacy's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| J Vasconi | Dominos Pizza | 58 | |
| Kevin Thomson | Barrick Gold Corp | 67 | |
| Deni Nicoski | Barrick Gold Corp | N/A | |
| Joseph Jordan | Dominos Pizza | 50 | |
| Stuart Levy | Dominos Pizza | 48 | |
| Darian Rich | Barrick Gold Corp | 63 | |
| Scott Hinshaw | Dominos Pizza | 56 | |
| Joe Jordan | Dominos Pizza | N/A | |
| Russell Weiner | Dominos Pizza | 56 | |
| Tom Curtis | Dominos Pizza | 54 | |
| Robert Krcmarov | Barrick Gold Corp | 55 | |
| Jeffrey Lawrence | Dominos Pizza | 45 | |
| Stan Gage | Dominos Pizza | 47 | |
| Robert Bafundo | Rave Restaurant Group | 62 | |
| Kelly Garcia | Dominos Pizza | 48 | |
| Scott Toop | The Wendys Co | 60 | |
| Stu Levy | Dominos Pizza | 47 | |
| Stanley Gage | Dominos Pizza | 50 | |
| Art Elia | Dominos Pizza | N/A | |
| Kevin Morris | Dominos Pizza | 63 | |
| Sandeep Reddy | Dominos Pizza | 53 | |
Management Performance
| Return On Equity | -0.0059 | |||
| Return On Asset | -0.21 |
Diplomat Pharmacy Leadership Team
Elected by the shareholders, the Diplomat Pharmacy's board of directors comprises two types of representatives: Diplomat Pharmacy inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Diplomat. The board's role is to monitor Diplomat Pharmacy's management team and ensure that shareholders' interests are well served. Diplomat Pharmacy's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Diplomat Pharmacy's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shawn Tomasello, Independent Director | ||
| Jeffrey Park, Director | ||
| Brian Griffin, Chairman of the Board, CEO | ||
| Gary Kadlec, President Director | ||
| Daniel Davison, CFO, Treasurer | ||
| Philip Hagerman, Chairman of the Board, CEO, Co-Founder | ||
| Dan Davison, CFO, Treasurer | ||
| Gary Rice, Executive Vice President - Operations | ||
| Kenneth Klepper, Independent Director | ||
| Sean Whelan, CFO, Treasurer, Secretary, Director | ||
| Joel Saban, President | ||
| Robyn Peters, Executive Vice President of Sales and Payor Strategies | ||
| Benjamin Wolin, Independent Director | ||
| Paul Urick, President | ||
| Atheer Kaddis, Senior Vice President Sales and Business Development, Director | ||
| Asher Dewhurst, IR Contact Officer | ||
| Atul Kavthekar, CFO | ||
| Regina Benjamin, Independent Director | ||
| Dave Loschinskey, COO | ||
| Terri Powers, Vice President Investor Relations | ||
| David Dreyer, Independent Director |
Diplomat Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Diplomat Pharmacy a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0059 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (6.50) % | |||
| Operating Margin | (0.12) % | |||
| Current Valuation | 881.17 M | |||
| Shares Outstanding | 76 M | |||
| Shares Owned By Insiders | 23.99 % | |||
| Shares Owned By Institutions | 85.41 % | |||
| Number Of Shares Shorted | 2.98 M | |||
| Price To Earning | 207.10 X |
Pair Trading with Diplomat Pharmacy
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Diplomat Pharmacy position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Diplomat Pharmacy will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ATyr Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATyr Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATyr Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling aTyr Pharma to buy it.
The correlation of ATyr Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATyr Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if aTyr Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ATyr Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Diplomat Stock
If you are still planning to invest in Diplomat Pharmacy check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Diplomat Pharmacy's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |